Products for Research Use Only

PRT062607 (acetate)

CAT: 0804-HY-15324-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15324-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate exerts potent antitumor activity in tumor xenograft mouse models[1].[2].
CAS Number
1370261-98-5
Product Name Alternative
P505-15 (acetate) ; PRT-2607 (acetate) ; BIIB-057 (acetate)
UNSPSC
12352005
Target
Apoptosis; FAK; Mixed Lineage Kinase; PAK; Pyk2; Src; Syk
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/prt062607-acetate.html
Purity
99.83
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
NC(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(N4N=CC=N4)=C3)=O.OC(C)=O
Molecular Formula
C21H27N9O3
Molecular Weight
453.50
References & Citations
[1]Spurgeon SE, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013 Feb;344 (2) :378-87.|[2]Coffey G, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340 (2) :350-9.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Lck; PAK5